Ibogaine Safety
Cardiac Screening & Medical Protocols

Medical Intake

Every prospective patient completes a detailed health history questionnaire covering cardiovascular history, psychiatric history, neurological conditions, current and past medications, and a full substance use timeline. A psychiatric evaluation screens for active psychosis, treatment-resistant conditions, and psychological contraindications. No patient advances to the cardiac screening stage until our medical team has reviewed and accepted their full intake documentation.

Cardiac Screening

A 12-lead EKG is submitted and reviewed by a physician for QTc interval, QRS morphology, and arrhythmia patterns. A comprehensive blood panel is required, including a complete metabolic panel, electrolyte assessment (potassium, magnesium, calcium), liver function tests, complete blood count, and urine drug screen. Patients with cardiac history or abnormal EKG findings are required to submit a cardiology evaluation or echocardiogram prior to acceptance. CYP2D6 genotyping is recommended for all patients and required for those with hepatic abnormalities.

Individualized Protocol Design

Our medical director designs an individualized dosing protocol based on each patient's weight, metabolic profile, substance use history, psychiatric assessment, and cardiac screening results. There is no standard dose at MindScape. Every protocol is built from the patient's specific clinical data upward. Medication management plans — tapering schedules, bridging protocols, and pre-treatment abstinence windows — are finalized and communicated to the patient before any deposit is taken.

Monitored Treatment

Throughout the active treatment session, patients are connected to continuous cardiac telemetry monitoring with real-time QTc tracking. Pulse oximetry and blood pressure are recorded at regular intervals. A board-certified physician and registered nurse are physically present on-site for the entire duration of the experience — not on-call, not available by phone, but in the room. Emergency medications including IV magnesium sulfate, lidocaine, epinephrine, atropine, and a defibrillator are immediately accessible. A hospital with cardiac capabilities is within 10 minutes of our facility under a signed transfer agreement.

Post-Treatment Observation

A minimum 72-hour post-treatment observation period is required for all patients. This is the window of greatest cardiac risk as ibogaine and its active metabolite noribogaine clear the system. Repeat EKG is performed within 24 hours post-treatment and again before discharge. Vital signs including blood pressure, heart rate, oxygen saturation, and temperature are monitored at regular intervals throughout the observation window. Patients are not discharged until the treating physician has confirmed safe QTc normalization and clinical stability.

Yes — and we believe it is important to be direct about this. Ibogaine-related deaths have occurred at facilities that did not conduct adequate cardiac screening, did not manage medication interactions appropriately, or did not have proper medical supervision in place during treatment. A 2021 review in the journal Frontiers in Pharmacology identified cardiac arrhythmia, typically in patients with pre-existing cardiac abnormalities or dangerous drug combinations, as the primary mechanism in ibogaine fatalities. Every single known fatality had one or more of these factors present. MindScape's zero-complication record across 900+ patients is the direct result of our mandatory EKG screening, comprehensive medication review, and 24/7 physician oversight. When these protocols are followed rigorously, ibogaine has a strong safety profile. When they are bypassed, the risk becomes unacceptable.

The QT interval is the portion of your heart's electrical cycle that represents the time it takes for the ventricular muscle cells to electrically reset between beats. When this interval is abnormally prolonged — a condition called QT prolongation — it creates a window of vulnerability during which the heart can spontaneously depolarize and enter a dangerous arrhythmia called Torsades de Pointes. If untreated, this can deteriorate into ventricular fibrillation and cardiac arrest. Ibogaine prolongs the QTc interval as part of its pharmacological action. This effect is manageable and safe in patients with normal baseline cardiac function and normal electrolytes. It becomes dangerous in patients who already have a prolonged QTc, electrolyte imbalances (particularly low potassium or magnesium), or structural heart abnormalities. This is why the 12-lead EKG and electrolyte panel are the two most important elements of our pre-treatment screening.

Yes, but it requires careful planning and a mandatory bridging protocol that takes a minimum of two weeks to complete. Methadone independently prolongs the QTc interval — sometimes significantly, particularly at higher doses — and combining it with ibogaine creates an additive risk that our team considers unacceptable without prior transition. The standard protocol requires transitioning from methadone to a short-acting opioid (typically morphine or oxycodone) for a minimum of 14 days prior to treatment. This reduces the cardiac risk to manageable levels and allows us to treat effectively. We manage this bridging process collaboratively with you and, where possible, your prescribing physician. If you are on methadone, this is not a disqualifying factor — it is a scheduling and preparation factor. Contact us and we will walk you through the process.

Our emergency response infrastructure is designed for immediate, physician-led intervention. A board-certified physician is physically present in the treatment room throughout the session — not on call, not a short drive away, but present. All standard Advanced Cardiac Life Support (ACLS) medications are on-site: IV magnesium sulfate for QT management, lidocaine, epinephrine, atropine, and a cardiac defibrillator. Our nursing staff are trained in ACLS protocols. In the event of a cardiac or other medical emergency requiring hospital-level care, we have a signed transfer agreement with a cardiac-capable hospital located within 10 minutes of our facility. Our clinical director conducts a full debrief of every medical event regardless of severity, and our protocols are updated continuously based on our clinical experience.

Cardiac monitoring is continuous throughout the active treatment session, which typically spans 12 to 24 hours depending on the protocol. Following the acute experience, vital sign checks including blood pressure, heart rate, and oxygen saturation are performed at regular intervals during a mandatory minimum 72-hour post-treatment observation period. A repeat 12-lead EKG is performed within 24 hours post-treatment and again prior to discharge. This extended monitoring window reflects the pharmacokinetics of both ibogaine and its primary active metabolite noribogaine, which has a longer half-life and continues to exert cardiac effects for days after the initial dose. No patient is discharged from our facility until the treating physician has confirmed that QTc has normalized and all vitals are within safe parameters.

Yes. Ibogaine is not a scheduled substance under Mexican federal law, making it legal to possess, administer, and use in clinical settings in Mexico. MindScape Retreat operates within Mexican medical and regulatory frameworks, with licensed physicians on staff and a fully documented clinical operation. This legal context is one of the reasons why Mexico — and Cozumel specifically — has become a leading destination for patients from the United States, Canada, and Europe who seek ibogaine treatment that is not available legally in their home countries. Our legal standing also means we can operate openly, maintain thorough medical records, and provide a level of clinical documentation and accountability that underground or grey-market providers cannot.

If our pre-treatment screening identifies a cardiac condition, medication interaction, or other contraindication that makes ibogaine treatment unsafe for you at this time, we will tell you clearly, explain the specific reason, and discuss what options exist. This may include a referral to a cardiologist for further evaluation before reconsidering your candidacy, a recommendation for a structured medication taper to resolve a pharmacological contraindication, or a discussion of alternative treatments. In some cases, 5-MeO-DMT therapy — which does not carry the same cardiac QT risk as ibogaine — may be appropriate for patients who cannot safely receive ibogaine. We will never accept a patient whose safety we cannot confidently guarantee. Our clinical reputation — and more importantly, your life — depends on maintaining that standard without exception.

Our intake team will provide a complete document checklist when you begin the application process. At a minimum you will need a 12-lead EKG performed within the last 30 days, a comprehensive metabolic panel and liver function tests from within the last 30 days, a complete list of all current medications and supplements including dosages and duration, and a urine drug screen. If you have any cardiac history, prior arrhythmias, structural heart conditions, or a family history of sudden cardiac death or long QT syndrome, an echocardiogram and cardiology clearance letter will be required. We coordinate the timing of all required tests with you during the pre-admission phase and can provide guidance on what to request from your physician. The clearer and more complete your records are, the faster and more thorough our medical team can make their assessment.